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Abstract Tumor necrosis factor-K (TNFK) has profound effects
on cultured adipocytes, one of which is the inhibition of terminal
differentiation. Previous studies in TNF receptor (TNFR)-
deficient preadipocytes have demonstrated that the anti-adipo-
genic effect of both secreted and transmembrane TNFK is
mediated solely by TNFR1. In this study, we performed a
structure^function analysis of the intracellular domains of
TNFR1 and investigated the signaling pathway(s) involved in
TNFR1-mediated inhibition of adipocyte differentiation. Our
results show that repression of adipogenesis required the
juxtamembrane and death domains and was independent of
the pathways involving nuclear factor UB and neutral sphingo-
myelinase. ß 2001 Published by Elsevier Science B.V. on be-
half of the Federation of European Biochemical Societies.
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1. Introduction
The multiple biological functions of tumor necrosis factor-K
(TNFK) are mediated by two distinct TNF receptors, TNFR1
and TNFR2. These two receptors have no homology in the
intracellular domains but exhibit a low degree of similarity in
the ligand binding regions located in the extracellular do-
mains, indicating that they are capable of inducing distinct
cellular responses [1]. So far, the majority of TNFK activities
have been attributed to TNFR1 though it has been reported
that TNFR2 can also mediate many cellular responses [1,2].
In adipocytes both TNF receptors are active and signal for a
variety of functions but TNFK-induced inhibition of adipo-
genesis is mediated only by TNFR1. However, no structure^
function analysis of this receptor has been reported in adipo-
cytes.
Signaling pathways utilized by each TNFR have been ex-
tensively studied in other cell types. No intrinsic catalytic
activity has been observed for either TNFR and they signal
through recruiting cytosolic factors upon ligand-induced oli-
gomerization [3,4]. Several functional domains have been re-
vealed in TNFR1 through structure^function analyses. The
death domain, a 80 amino acid region located to the C-termi-
nus of TNFR1, signals apoptosis, activation of nuclear factor
(NF)-UB and c-Jun N-terminal kinase. All the above functions
are ful¢lled through the interaction between the death domain
and TRADD (TNFR1-associated death domain protein) [5].
Several downstream e¡ectors of TRADD have been identi-
¢ed, including FADD (Fas-associated death domain protein),
TRAF2 (TNFR-associated factor 2) and RIP (receptor inter-
action protein). The direct interaction between TRADD and
FADD [4,6] is responsible for signaling apoptosis by sequen-
tially activating caspase 8 (Flice/MACH/Mch5) [7] and cas-
pase 10 (Flice2/Mch4). The interactions between TRADD and
TRAF2 as well as RIP are essential in TNFK-mediated
NF-UB activation [4,8]. Recently, a regulatory factor of death
domain-containing receptors was identi¢ed and named si-
lencer of death domains (SODD) [9]. This provides a negative
feedback mechanism of controlling death domain protein sig-
naling.
In addition to the death domain, two other regions of
TNFR1 have also been found to physically recruit other fac-
tors: the NSD motif (neutral sphingomyelinase (N-SMase)
activating domain) and the juxtamembrane domain (JM).
The NSD motif is a region containing nine amino acid resi-
dues located immediately proximal to the death domain. It
interacts with a WD-repeat protein, FAN (factor associated
with N-SMase activation) [10], and activates membrane
N-Smase, which produces the lipid signaling molecule ceram-
ide through hydrolyzing plasma membrane sphingomyelin.
The juxtamembrane region of TNFR1 contains about 100
amino acids and interacts with an isoform of phosphatidyl-
inositol-4-phosphate-5-kinase (PIP5K), which produces phos-
phatidylinositol 4,5-bisphosphate [11], a precursor of the im-
portant second messengers phosphatidyl 1,4,5-triphosphate
and 1,2-diacylglycerol.
The intracellular domain (ID) of TNFR1 has also been
found to interact with a number of other molecules, such as
Grb2, TNFR-associated kinase, mitogen-activated protein
(MAP) kinase activating death domain protein and TNFR-
associated protein [12^15], which adds more information to
a comprehensive understanding of TNFR1 signaling path-
ways.
Here, we examine the TNFR1 functional domains that are
responsible for mediating the anti-adipogenic e¡ects of trans-
membrane TNFK (mTNF) and demonstrate that several path-
ways are involved in this TNFK-mediated cellular response.
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2. Materials and methods
2.1. Cells and reagents
TNFR13=3R23=3 cell lines were established as described previously
[16] and tested for their capacity to di¡erentiate into adipocytes. The
best di¡erentiating line only yielded 6 80% adipocytes and was fur-
ther improved by subcloning. Among the 50 clones tested for adipo-
genic potential, a clone which yielded almost 100% adipocytes was
identi¢ed and used for all the experiments. The absence of endoge-
nous TNFRs was con¢rmed by genotyping and Northern blot anal-
ysis. Recombinant murine soluble TNFK (sTNF) was purchased from
Genzyme (Cambridge, MA, USA). Hygromycin B and puromycin
were from Sigma (St. Louis, MO, USA).
2.2. Vector construction
Cloning of the mTNFv1^9K11E and TNFR1 cDNAs into retro-
viral vectors containing hygromycin B and puromycin resistance
genes, respectively, has been described in our previous study [17].
Mutagenesis of TNFR1 cDNA was performed in pBluescript vector.
Two of the deletion mutants, TNFR1vID and TNFR1vDD, were
produced by introducing stop codons at residues 234 (ATG to
TAG) and 354 (GCA to TGA), respectively, using the Chameleon
double-stranded, site-directed mutagenesis kit (Stratagene, La Jolla,
CA, USA). The primers used were 5P-CCGGGGATATCGGCACTA-
TAAACTGATGAAG and 5P-CAGAATCGCAAGGTCTCAATTG-
TCAGGACGTTGC. The other three deletion mutants, TNFR1vJM,
TNFR1vNSM and TNFR1vNSMvDD, and the hybrid mutant
TNFR2/R1 were generated through ligation of PCR fragments. To
delete the JM, the extracellular (ED) and transmembrane portions
(TM) of TNFR1 were ampli¢ed by PCR (5P primer
CCCGGGATGGGTCTCCCCACCGTGCCTGGC and 3P primer
GGTACCTAAACTGATGAAGATAAAGGATAGAAGGC) and li-
gated to the rest of the intracellular domain (without JM, ampli¢ed by
5P primer GGTACCACCTCTGTTCAGAAATGGGAAGACTCC-
GCC and 3P primer TTATCGCGGGAGGCGGGTCGTGGAC),
which introduced a KpnI site. To delete the NSM, the upstream region
of NSM was ampli¢ed by PCR (5P primer CCCGGGATGGGTCT-
CCCCACCGTGCCTGGC and 3P primer GGTACCTGGCACG-
GAGCAGAGTGATTCG) and ligated to the death domain (ampli-
¢ed by 5P primer GGTACCGACAATGCAGACCTTGCG and
3P primer TTATCGCGGGAGGCGGGTCGTGGAC), which also
introduced a KpnI site. The TNFR1vNSMvDD mutant was created
by amplifying the cDNA encoding ED+TM+JM, with a stop codon
introduced at the end of JM (5P primer GGTACCGACAATGCA-
GACCTTGCG and 3P primer GGGTTATGGCACGGAGCA-
GAGTGATTCG). Finally, the hybrid mutant TNFR2/R1 was cre-
ated by ligating the PCR fragments of the TNFR2 extracellular
domain (ampli¢ed by the use of 5P primer CCCGGGATGGC-
GCCCGCCGCCCTCTGGGTC and 3P primer GGTACCTTGTT-
CAATAATGGGGGTTGAACCCAACG) to TNFR1 TM and ID
(ampli¢ed by 5P primer GGTACCGCGGTGCTGTTGCCCCTGGT-
TATCTTG and 3P primer TTATCGCGGGAGGCGGGTCGTG-
GAC), which also introduced a KpnI site. All PCR products were
con¢rmed by sequencing and the ¢nal TNFR1 mutants were cloned
into a retroviral vector containing the puromycin resistance gene for
expression in the pre-adipocytes.
2.3. Transfection and infection
TNFR1 mutants were ¢rst transiently transfected into Bosc 23 cells
with the Cell Phect calcium phosphate coprecipitation kit (Amersham
Pharmacia Biotech) to obtain infectious viral particles [18]. Forty-
eight hours after transfection, supernatants containing viral particles
were collected, ¢ltered and incubated with recipient cells, as de-
scribed previously. In this study, mTNFv1^9K11E expressing
TNFR13=3R23=3 cells were used as recipient cells to achieve coex-
pression of mTNF and TNFR1 or one of the TNFR1 mutants. Puro-
mycin was used at a concentration of 5 Wg/ml for initial 7-day selec-
tion and then stable cell lines were maintained in the presence of both
puromycin (4 Wg/ml) and hygromycin B (200 Wg/ml) for all the experi-
ments.
2.4. Total RNA preparation and Northern blotting
The guanidinium thiocyanate method was used to extract all RNA
samples [19]. Denatured RNAs were loaded on 1% agarose gel con-
taining 3% formaldehyde. Biotran membrane (ICN) was used for
transferring RNA after electrophoresis. After UV cross-linking and
baking membranes at 80‡C for 1 h, [K-32P]dCTP- (NEN Life Science
Products, Boston, MA, USA) labeled cDNA probes were added to
hybridization bu¡er for overnight incubation. After proper washings,
blots were exposed to X-omat ¢lms and signals were quantitated by
the use of NIH image software with 18S rRNA as loading adjustment.
2.5. NF-UB activation
TNFR13=3R23=3 cells expressing TNFR1 mutants or control vec-
tors for TNFRs or mTNF were cotransfected with a NF-UB pro-
moter-driven luciferase reporter gene (provided by Dr. Christopher
K. Glass, University of California, San Diego, CA, USA) using the
lipofectamine-plus kit (Gibco-BRL Life Science, Grand Island, NY,
USA). sTNF was added to the medium at a concentration of 10 ng/ml
for 3 or 10 h before harvest which was done 48 h after transfection.
The luciferase activity was determined by a luminometer and cor-
rected for transfection e⁄ciency as assessed by L-galactosidase assays.
2.6. Cell di¡erentiation analysis
TNFR13=3R23=3 preadipocytes were grown in Dulbecco’s modi-
¢ed Eagle’s medium (DMEM, Life Technologies) supplemented with
10% bovine calf serum (Hyclone, Logan, UT, USA). Transfected cells
were grown in the same medium in the presence of 200 Wg/ml hygrom-
ycin B (Sigma) and 4 Wg/ml puromycin (Sigma). For di¡erentiation,
cells were seeded at 1.0U106 on 10-cm petri dishes, grown to 80%
con£uence in DMEM supplemented with 10% cosmic calf serum (Hy-
clone) and induced by adipogenic reagents for 4 days (5 Wg/ml insulin,
1 WM dexamethasone, 0.5 mM isobutylmethylxanthine and 1 WM
BRL49653). Then, cells were kept in medium containing insulin until
the vector-infected controls fully di¡erentiated. Adipocyte di¡erentia-
tion was evaluated by oil red O staining, microscopy and mRNA
expression of adipogenic markers.
3. Results
3.1. Expression of TNFR1 mutants in TNFR13=3R23=3
preadipocyte cell lines and NF-UB activation
Our previous studies have demonstrated that both sTNF
and mTNF could inhibit adipocyte di¡erentiation. TNFR1
alone is su⁄cient to mediate this anti-adipogenic e¡ect and
no potentiation by TNFR2 was observed [17]. To further
dissect the signaling pathway(s) utilized by TNFR1 in this
action, TNFR1 mutants lacking several functional domains
were generated (Fig. 1A). These included the JM, the DD
and the NSM. A deletion mutant without the ID was used
as a positive control for di¡erentiation analysis. To determine
whether the use of TNFR1 versus TNFR2 is due to selective
binding of TNFK to TNFR1 or speci¢c to TNFR1 signaling,
a hybrid mutant with the TNFR2 extracellular domain and
TNFR1 transmembrane as well as intracellular domains was
created. All the above mutants were expressed in
TNFR13=3R23=3 cells using retroviral vectors, which was
con¢rmed by examining mRNA (Fig. 1B) and protein levels
(Fig. 1C). We noticed that mutants without the DD tended to
have signi¢cantly higher levels of expression with the excep-
tion of TNFR1vNSM (Fig. 1B, lanes 2, 5 and 7). The mem-
brane-bound form of TNFK was stably expressed in these
C
Fig. 1. Mutagenesis of TNFR1. A: Schematic design of TNFR1
mutants. B: mRNA levels of TNFR1 mutants. Top panel is probed
with the full-length cDNA for mouse TNFR1. Middle panel is
probed with the cDNA of mouse TNFR2 extracellular domain. The
expression of membrane-bound TNF is also shown (mTNF). C:
Protein levels of TNFR1 mutants. Protein levels are determined by
immunoblotting cellular extracts with a monoclonal antibody
against mouse TNFK.
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cells lines and did not exhibit signi¢cant di¡erences in its
expression levels.
NF-UB activation was examined to con¢rm that mutants
with the DD are functional despite being expressed at rela-
tively low levels by determining the activity of a NF-UB pro-
moter-driven luciferase reporter gene construct. As shown in
Fig. 2, the luciferase reporter gene was activated in
TNFR13=3R23=3 cells expressing wild-type TNFR1,
TNFR1vJM and TNFR1vNSM upon TNFK stimulation.
The TNFR2/R1 hybrid did not show any function in NF-
UB activation though it contains the DD. This is likely to
be related to the fact that TNFR2 only activates NF-UB in
certain cell types.
3.2. Di¡erentiation analysis of TNFR1 mutant-expressing
TNFR13=3R23=3 cell
TNFR13=3R23=3 cells simultaneously expressing each of
the above mutants and mTNFv1^9K11E were induced for
di¡erentiation to determine the domains responsible for the
TNFR1-mediated anti-adipogenic e¡ect. A mixture of 5 Wg/ml
insulin, 1 WM dexamethasone, 0.5 mM isobutylmethylxan-
thine and 1 WM BRL49653 was used for a 4-day induction
period. Cells were then maintained in medium containing only
insulin until vector-infected cells were fully di¡erentiated. Ex-
periments were then terminated for morphological and molec-
ular comparison of vector-infected control cells with those
expressing TNFR1 mutants. As shown in Fig. 3, vector-in-
fected control cells fully di¡erentiated into lipid-laden adipo-
cytes that can be readily identi¢ed by oil red O staining. In
contrast, cells transfected with wild-type TNFR1 di¡erenti-
ated poorly, indicating inhibition of adipogenesis. Cells ex-
pressing TNFR1vID di¡erentiated to a similar extent as con-
trol cells, suggesting that TNFR1 signaling pathway(s) is
necessary for this repression. The fact that the hybrid mutant
TNFR2/R1 could also inhibit di¡erentiation further con-
¢rmed the necessity of TNFR1 intracellular signaling rather
than selective ligand binding. TNFR1 mutants lacking either
JM or DD lost their ability to repress adipocyte di¡erentia-
tion, indicating the involvement of both pathways. Cells ex-
pressing TNFR1vNSM inhibited di¡erentiation to the same
extent as wild-type TNFR1 did, which excluded the involve-
ment of NSD. The TNFR1 mutant lacking both NSD and
DD behaved similarly to that lacking only DD.
In order to evaluate the e¡ects of TNFR1 mutants on adi-
pocyte di¡erentiation at the molecular level, we next examined
expression levels of four adipogenic markers: Glut4, peroxi-
some proliferator-activated receptor-Q (PPARQ), adipsin and
Fig. 2. NF-UB activation by TNFR1 mutants. Open bars, no TNFK
treatment; ¢lled bars, treatment with 10 ng/ml recombinant TNFK
for 3 h; hatched bars, treatment with 10 ng/ml soluble TNFK for
10 h. Vec, vector-transfected control cells. The results represent
mean þ S.E.M. of data obtained from three independent experi-
ments.
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aP2. The expression levels of all these genes were signi¢cantly
decreased in cells expressing wild-type TNFR1, the hybrid
mutant TNFR2/R1 and TNFR1vNSM compared to control
cells expressing TNFR1vID (Fig. 4A, lanes 1, 3, 6 and 2).
Expression of all adipocyte genes was signi¢cantly repressed
in TNFR13=3R23=3 cells expressing TNFR1vJM,
TNFR1vDD and TNFR1vNSMvDD (Fig. 4A, lanes 4,
5 and 7). Quantitation of three independent experiments is
shown in Fig. 4B. These results are consistent with the ob-
served morphological changes, con¢rming that the anti-adipo-
genic e¡ect of TNFK is mediated by more than one signaling
pathway after aggregation of TNFR1.
4. Discussion
TNFK has profound e¡ects on adipocytes, which include
suppression of di¡erentiation, inhibition of insulin-stimulated
glucose and free fatty acid uptake and lipogenesis, stimulation
of lipolysis and regulation of gene expression. Extensive anal-
yses have primarily focused on the actions of sTNF on adi-
pocyte biology. Our previous studies have demonstrated that
mTNF is also biologically active in cultured adipocytes [17].
Interestingly, when expressed in adipocytes, TNFK primarily
resides on the cell surface and is processed quite ine⁄ciently
to produce secreted protein (Xu and Hotamisligil, unpub-
Fig. 3. Di¡erentiation analysis of TNFR13=3R23=3 cells simultaneously expressing mTNFv1^9K11E and TNFR1 mutants. A: Microscopy of
these cells stained with oil red O after completion of the di¡erentiation procedure. B: An overall view of the same cells on whole plates stained
with oil red O.
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lished data). In addition, although mTNF has been proposed
to be a prime ligand for TNFR2 [20], in adipocytes it acts
through TNFR1, alone, to mediate the anti-adipogenic e¡ect
[17]. In this study, we investigated the potential functional
domains of TNFR1 involved in this e¡ect by establishing a
series of TNFR1 mutants and performing a structure^func-
tion analysis. By coexpressing these TNFR1 mutants and a
membrane-bound TNFK variant (mTNFv1^9K11E) in
TNFR13=3R23=3 preadipocytes, we were able to demonstrate
that both JM and DD of TNFR1 are critical in signaling for
the TNF-mediated suppression of adipogenesis.
Our data reveal several critical aspects of TNFR1 signaling
as it relates to TNFK actions in adipocytes. First, it appears
that activation of NF-UB, alone, is neither necessary nor suf-
¢cient for the TNFK-mediated inhibition of adipocyte di¡er-
entiation. The vJM mutant fully activates NF-UB but has no
e¡ect on di¡erentiation. Conversely, the TNFR2/R1 chimera
blocks di¡erentiation without the activation of NF-UB. Sec-
ond, the NSD is dispensable for both NF-UB activation and
inhibition of adipogenesis, whereas the JM is necessary for the
e¡ects on di¡erentiation but not NF-UB activity. Finally, the
DD is critically involved in signaling for both of these activ-
ities.
There are several potential downstream e¡ectors that might
require these functional domains. For example, the JM of
TNFR1 interacts with PIP5K. It has been reported that
PIP5K activity is linked to cell proliferation as well as malig-
nancy [22] and blockage of PIP5K function via the use of
monoclonal antibodies can block the proliferatory e¡ect in
response to plasma-derived growth factor (PDGF) and bom-
besin [23]. PDGF and several other mitogenic factors such as
epidermal and ¢broblast growth factors and TNFK can also
regulate PPARQ activity through activation of the MAP ki-
nase pathway [21]. Since PPARQ is a critical regulator of adi-
pocyte growth and di¡erentiation, one potential mechanism
for the requirement of an intact JM domain involves PIP5K-
mediated regulation of growth and di¡erentiation signals for
adipogenesis. On the other hand, the DD has also been shown
to be critical for several di¡erent pathways impacting similar
cellular processes, including acidic SMase-mediated ceramide
signaling. As a lipid second messenger, ceramide has been
demonstrated to activate MAP kinase cascades through stim-
ulating a Ser/Thr ceramide-activated protein kinase [24],
which can be a potential mechanism to explain the involve-
ment of the DD in adipogenesis. Additional studies should
further dissect these pathways.
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